FMP

FMP

Enter

Natera, Inc. (NASDAQ: NTRA) Advances in Colorectal Cancer with Promising Clinical Trial Results

- (Last modified: Jan 27, 2025 9:04 AM)

twitterlinkedinfacebook
blog post cover photo

Image credit: Google Images

  • Natera's Phase III clinical trial shows significant improvements in disease-free survival and overall survival for colorectal cancer patients using Signatera.
  • The company's focus on personalized medicine is highlighted by the ability of Signatera to predict the benefit of celecoxib in improving patient outcomes.
  • Despite a slight decrease in stock price, Natera's market capitalization and trading volume on the NASDAQ:NTRA remain strong.

Natera, Inc. (NASDAQ: NTRA) is a prominent player in the field of cell-free DNA and genetic testing. The company focuses on developing and commercializing molecular diagnostic tests that help in the early detection and management of various diseases, including cancer. Natera's competitors include companies like Illumina and Guardant Health, which also specialize in genetic testing and diagnostics.

Natera recently announced successful results from the Phase III CALGB (Alliance) / SWOG 80702 clinical trial in colorectal cancer. The trial, involving around 1,000 patients, showed that Signatera-positive patients experienced significant improvements in disease-free survival (DFS) and overall survival (OS) with the addition of celecoxib to standard chemotherapy. Specifically, the three-year DFS for these patients was 44.1%, compared to 26.6% for those not receiving celecoxib.

Dr. Alexey Aleshin, Natera's corporate chief medical officer, emphasized the importance of these findings in advancing personalized medicine for colorectal cancer patients. The study highlights Signatera's ability to predict the benefit of celecoxib, a well-tolerated therapy, in improving patient outcomes. This aligns with Natera's commitment to integrating personalized diagnostics into standard care to enhance health outcomes.

In addition to the CALGB trial, results from the ALTAIR clinical trial were presented. This trial explored treatment escalation with Trifluridine/Tipiracil (FTD/TPI) in colorectal cancer patients. Although it did not achieve statistical significance overall, it showed a significant benefit for resected oligometastatic stage IV patients treated with FTD/TPI. Signatera, a personalized molecular residual disease test, is designed to detect cancer recurrence earlier than standard tools, aiding in treatment decisions.

On the financial front, Natera's Chief Financial Officer, Brophy Michael Burkes, recently sold 687 shares of Common Stock at $171.80 each. Despite this sale, he still owns 109,733 shares. The stock is currently priced at $167.61, reflecting a decrease of 2.45%. NTRA has a market capitalization of approximately $22.13 billion, with a trading volume of 884,394 shares on the NASDAQ:NTRA exchange.

Other Blogs

Sep 10, 2024 11:33 AM - Parth Sanghvi

Best Alternatives to Yahoo Finance for Downloading Historical Stock Data

When it comes to downloading historical stock data, Yahoo Finance has been a popular choice for many. However, for those looking for more comprehensive, accurate, and flexible options, Financial Modeling Prep (FMP) offers a suite of powerful tools and services that stand out as superior alternatives...

blog post title

Nov 8, 2024 10:30 AM - Sanzhi Kobzhan

Understanding Equity Valuation: When to Use DCF, DDM, and Price-Income (Multiplicators) Models

When it comes to investing in stocks, one of the key decisions an investor must make involves determining the intrinsic value of a company's shares. Equity valuation isn't just about numbers, it's an art mixed with science, aiming to predict future performance based on current and historical data. H...

blog post title

Nov 22, 2024 10:08 AM - Parth Sanghvi

Fundamental Analysis: Principles, Types, and How to Use It

Fundamental analysis is one of the most essential tools for investors and analysts alike, helping them assess the intrinsic value of a stock, company, or even an entire market. It focuses on the financial health and economic position of a company, often using key data such as earnings, expenses, ass...

blog post title
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep